Improvement of tracheal autograft revascularization by means of fibroblast growth factor

Albes, Johannes M.; Klenzner, Thomas; Kotzerke, Jörg; Thiedemann, Klaus U.; Schäfers, Hans‐Joachim; Borst, H. G.

doi:10.1016/0003-4975(94)91015-4

Cited by 46 publications

(26 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23,37,38 This characteristic of bFGF may be of interest for clinical applications, such as endothelial cell-seeded vascular grafts, as can be deduced from animal studies. 39,40 However, to minimize the possibility of tumor formation or enhancement, the mitogen needs to be directed to the appropriate site of action. 41 Therefore, local release of bFGF is preferred over systemic administration of the growth factor.…”

Section: Discussionmentioning

confidence: 99%

Proliferation of endothelial cells on surface-immobilized albumin-heparin conjugate loaded with basic fibroblast growth factor

Bos

Scharenborg

Poot

et al. 1999

J. Biomed. Mater. Res.

View full text Add to dashboard Cite

Seeding of endothelial cells (ECs) on the luminal surface of small-diameter vascular grafts is a promising method to avoid occlusion of these prostheses. Immobilization of basic fibroblast growth factor (bFGF) to substrates used to coat or fill porous prostheses may enhance the formation of a confluent monolayer of ECs. Human umbilical vein endothelial cells (HUVECs) were grown on bFGF-loaded albumin-heparin conjugate bound to CO2 gas-plasma-treated polystyrene. In the order of 2-3 ng/cm2 bFGF had to be immobilized to form a confluent monolayer of HUVECs. The most prominent effect of surface-immobilized bFGF was stimulation of the proliferation shortly after seeding, resulting within 3 days in confluent cell monolayers with high density. In contrast, in cultures with 0.3 ng/mL bFGF in the medium instead of bFGF bound to the surface, it took almost a week before the cell layers reached confluency. Binding of bFGF to heparin and the biological activity of bFGF towards ECs were not influenced by the (radio-)labeling of bFGF with iodine. However, only a minor part of the bFGF used in this study displayed heparin affinity. Furthermore, degradation and multimerization of labeled bFGF in time occurred when the growth factor was stored at 20 degrees -37 degrees C. This limits the use of labeled bFGF to short-term (hours) experiments. In conclusion, bFGF loading of vascular graft surfaces through complexation of bFGF with a heparin-containing matrix probably will lead to more rapid formation of a confluent monolayer of ECs on graft surfaces upon seeding of the cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Proliferation of endothelial cells on surface-immobilized albumin-heparin conjugate loaded with basic fibroblast growth factor

Bos

Scharenborg

Poot

et al. 1999

J. Biomed. Mater. Res.

View full text Add to dashboard Cite

show abstract

“…Baffour et al 3 also observed a significant formation of collaterals in ischemic extremities after growth factor administration in animals. Albes et al 27 produced a distinct improvement in the blood flow in ischemic tracheal segments implanted subcutaneously in rabbits by injecting growth factor-enriched fibrin glue locally.…”

Section: Discussionmentioning

confidence: 99%

Induction of Neoangiogenesis in Ischemic Myocardium by Human Growth Factors

et al. 1998

View full text Add to dashboard Cite

Background-The present article is a report of our animal experiments and also of the first clinical results of a new treatment for coronary heart disease using the human growth factor FGF-I (basic fibroblast growth factor) to induce neoangiogenesis in the ischemic myocardium. Methods and Results-FGF-I was obtained from strains of Escherichia coli by genetic engineering, then isolated and highly purified.Several series of animal experiments demonstrated the apathogenic action and neoangiogenic potency of this factor. After successful conclusion of the animal experiments, it was used clinically for the first time. FGF-I (0.01 mg/kg body weight) was injected close to the vessels after the completion of internal mammary artery (IMA)/left anterior descending coronary artery (LAD) anastomosis in 20 patients with three-vessel coronary disease. All the patients had additional peripheral stenoses of the LAD or one of its diagonal branches. Twelve weeks later, the IMA bypasses were selectively imaged by intra-arterial digital subtraction angiography and quantitatively evaluated. In all the animal experiments, the development of new vessels in the ischemic myocardium could be demonstrated angiographically. The formation of capillaries could also be demonstrated in humans and was found in all cases around the site of injection. A capillary network sprouting from the proximal part of the coronary artery could be shown to have bypassed the stenoses and rejoined the distal parts of the vessel. Conclusions-We believe that the use of FGF-I for myocardial revascularization is in principle a new concept and that it may be particularly suitable for patients with additional peripheral stenoses that cannot be revascularized surgically. (Circulation. 1998;97:645-650.)

show abstract

“…VEGF has a relatively short biological half-life owing to rapid biodegradation, which constitutes a major limitation for delivery of a recombinant protein (14). Fibrin sealants have already been tested as a means to deliver growth factors in animal models of wound healing and revascularization (15)(16)(17)(18). bFGF is released relatively slowly from the fibrin clot because of covalent binding of bFGF to fibrin(ogen) (19).…”

Section: Introductionmentioning

confidence: 99%

Fibrin Gel-Immobilized VEGF and bFGF Efficiently Stimulate Angiogenesis in the AV Loop Model

Arkudas¹,

Tjiawi²,

Bleiziffer³

et al. 2007

Mol Med

View full text Add to dashboard Cite

The modulation of angiogenic processes in matrices is of great interest in tissue engineering. We assessed the angiogenic effects of fibrin-immobilized VEGF and bFGF in an arteriovenous loop (AVL) model in 22 AVLs created between the femoral artery and vein in rats. The loops were placed in isolation chambers and were embedded in 500 µL fibrin gel (FG) (group A) or in 500 µL FG loaded with 0.1 ng/µL VEGF and 0.1 ng/µL bFGF (group B). After two and four weeks specimens were explanted and investigated using histological, morphometrical, and ultramorphological [scanning electron microscope (SEM) of vascular corrosion replicas] techniques. In both groups, the AVL induced formation of densely vascularized connective tissue with differentiated and functional vessels inside the fibrin matrix. VEGF and bFGF induced significantly higher absolute and relative vascular density and a faster resorption of the fibrin matrix. SEM analysis in both groups revealed characteristics of an immature vascular bed, with a higher vascular density in group B. VEGF and bFGF efficiently stimulated sprouting of blood vessels in the AVL model. The implantation of vascular carriers into given growth factor-loaded matrix volumes may eventually allow efficient generation of axially vascularized, tissue-engineered composites.

show abstract

Improvement of tracheal autograft revascularization by means of fibroblast growth factor

Cited by 46 publications

References 19 publications

Proliferation of endothelial cells on surface-immobilized albumin-heparin conjugate loaded with basic fibroblast growth factor

Proliferation of endothelial cells on surface-immobilized albumin-heparin conjugate loaded with basic fibroblast growth factor

Induction of Neoangiogenesis in Ischemic Myocardium by Human Growth Factors

Fibrin Gel-Immobilized VEGF and bFGF Efficiently Stimulate Angiogenesis in the AV Loop Model

Contact Info

Product

Resources

About